Galderma Group AG (SWX:GALD)

Market Cap	34.69B
Revenue (ttm)	3.73B
Net Income (ttm)	300.62M
Shares Out	237.41M
EPS (ttm)	1.26
PE Ratio	115.57
Forward PE	52.41
Dividend	0.07 (0.05%)
Ex-Dividend Date	Apr 25, 2025

Volume	62,891
Average Volume	393,959
Open	146.70
Previous Close	146.10
Day's Range	146.30 - 149.10
52-Week Range	72.70 - 148.80
Beta	n/a
RSI	66.48
Earnings Date	Oct 24, 2025

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,545
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

Financial numbers in USD